PromarkerD US Market Update Proteomics International rescinds PromarkerD exclusive licence deal with PrismHealthDx in US – negotiations brought forward with new tier 1 partners New immunoassay technology platform to accelerate PromarkerD rollout in US Clinical samples for first phase of CDx collaborative study received from Janssen Research & Development, LLC Key Opinion Leader (KOL) engagement to drive US demand for PromarkerD
Ann: PromarkerD US market update, page-3
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
70.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.35M | |||
| Open | High | Low | Value | Volume |
| 70.0¢ | 70.5¢ | 69.0¢ | $86.64K | 123.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1449 | 69.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 70.5¢ | 7250 | 1 |
View Market Depth
| Last trade - 15.31pm 18/11/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |